Comparative effects of Bcl-2 inhibition in canine and human breast cancer in vitro models - a review

Breast cancer is among the leading malignant pathologies in terms of incidence and mortality rates; therefore, rapid development of effective drug treatments, particularly for triple negative breast cancer (TNBC), is of critical importance. One promising approach to speed up the process of drug discovery capitalizes on repositioning of specific therapeutic molecules used for malignancies that have similar altered molecular profiles. In this study, ABT-199, a small molecule that elicits selective inhibition of Bcl-2 and effective against chronic lymphocytic leukemia, is repositioned for treating TNBC using both human and canine breast cancer cell lines. It is observed that ABT-199 elicits similar inhibitory effects, including apoptosis, cell cycle, and migration, on both human and canine breast cancer cells.